Demcizumab

Drug Profile

Demcizumab

Alternative Names: Anti-delta-like ligand 4 monoclonal antibody; Anti-DLL4 monoclonal antibody; OMP-18M21; OMP-21M18

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator OncoMed Pharmaceuticals
  • Developer Celgene Corporation; OncoMed Pharmaceuticals
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action DLL4 protein inhibitors; Stem cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer; Pancreatic cancer
  • Phase I/II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase I Solid tumours
  • No development reported Colorectal cancer

Most Recent Events

  • 01 Sep 2016 OncoMed Pharmaceuticals completes a phase Ib trial for Non-small cell lung cancer (combination therapy, first-line therapy, late-stage disease, metastatic disease, recurrent, inoperable/ unresectable) in Australia, New Zealand and Spain (NCT01189968)
  • 01 Sep 2016 OncoMed Pharmaceuticals completes enrolment in the phase II trial for Pancreatic cancer in Australia, Belgium, Canada, Spain, United states and United Kingdom
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Colorectal-cancer(Combination therapy, First-line therapy, Metastatic disease, Second-line therapy or greater) in Australia (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top